TY - JOUR
T1 - Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy
AU - Lee, Belle L.
AU - Padula, Ana M.
AU - Kimbrough, Robert C.
AU - Jones, Stephen R.
AU - Chaisson, Richard E.
AU - Mills, John
AU - Sande, Merle A.
PY - 1991/8/15
Y1 - 1991/8/15
N2 - To the Editor: Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.1 Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with Streptococcus pneumoniae2 In addition, its in vitro activity against gram-positive cocci is marginal.1 3 Minimal inhibitory concentrations for S. pneumoniae and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.4 We report here the cases of six patients. . .
AB - To the Editor: Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.1 Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with Streptococcus pneumoniae2 In addition, its in vitro activity against gram-positive cocci is marginal.1 3 Minimal inhibitory concentrations for S. pneumoniae and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.4 We report here the cases of six patients. . .
UR - http://www.scopus.com/inward/record.url?scp=0025740641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025740641&partnerID=8YFLogxK
U2 - 10.1056/NEJM199108153250719
DO - 10.1056/NEJM199108153250719
M3 - Letter
C2 - 1852190
AN - SCOPUS:0025740641
SN - 0028-4793
VL - 325
SP - 520
EP - 521
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 7
ER -